The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells

BackgroundThe cyclin-dependent kinase inhibitor p27 is a putative tumor suppressor that is downregulated in the majority of human prostate cancers. The mechanism of p27 down-regulation in prostate cancers in unknown, but presumably involves increased proteolysis mediated by the SCFSKP2 ubiquitin ligase complex. Here we used the human prostate cancer cell line LNCaP, which undergoes G1 cell cycle arrest in response to androgen, to examine the role of the SKP2 F-box protein in p27 regulation in prostate cancer.ResultsWe show that androgen-induced G1 cell cycle arrest of LNCaP cells coincides with inhibition of cyclin-dependent kinase 2 activity and p27 accumulation caused by reduced p27 ubiquitylation activity. At the same time, androgen decreased expression of SKP2, but did not affect other components of SCFSKP2. Adenovirus-mediated overexpression of SKP2 led to ectopic down-regulation of p27 in asynchronous cells. Furthermore, SKP2 overexpression was sufficient to overcome p27 accumulation in androgen arrested cells by stimulating cellular p27 ubiquitylation activity. This resulted in transient activation of CDK2 activity, but was insufficient to override the androgen-induced G1 block.ConclusionsOur studies suggest that SKP2 is a major determinant of p27 levels in human prostate cancer cells. Based on our in vitro studies, we suggest that overexpression of SKP2 may be one of the mechanisms that allow prostate cancer cells to escape growth control mediated by p27. Consequently, the SKP2 pathway may be a suitable target for novel prostate cancer therapies.

[1]  W. Zwerschke,et al.  Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. , 1996, Oncogene.

[2]  M. Pagano,et al.  Role of the F-box protein Skp2 in lymphomagenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Daniel A. Chamovitz,et al.  Arabidopsis COP9 is a component of a novel signaling complex mediating light control of development , 1994, Cell.

[4]  T. Hunter,et al.  Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFβ-treated cells , 1996, Nature.

[5]  L. Hengst,et al.  Translational Control of p27Kip1 Accumulation During the Cell Cycle , 1996, Science.

[6]  James M. Roberts,et al.  Cyclin E-CDK2 is a regulator of p27Kip1. , 1997, Genes & development.

[7]  James M. Roberts,et al.  Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. , 1995, Cancer research.

[8]  K. Polyak,et al.  p27KIP1, an inhibitor of cyclin-dependent kinases. , 1995, Progress in cell cycle research.

[9]  M. Loda,et al.  Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. , 2001, Molecular endocrinology.

[10]  J. Richie,et al.  Expression of cell cycle-regulated proteins in prostate cancer. , 1996, Cancer research.

[11]  D. S. Coffey,et al.  Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. , 1998, The American journal of pathology.

[12]  Esposito,et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.

[13]  J. Ecker,et al.  Arabidopsis Homologs of a c-Jun Coactivator Are Present Both in Monomeric Form and in the COP9 Complex, and Their Abundance Is Differentially Affected by the Pleiotropic cop/det/fus Mutations , 1998, Plant Cell.

[14]  I. Leav,et al.  Androgen‐supported estrogen‐enhanced epithelial proliferation in the prostates of intact noble rats , 1989, The Prostate.

[15]  R. Mamillapalli,et al.  PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27KIP1 through the ubiquitin E3 ligase SCFSKP2 , 2001, Current Biology.

[16]  C. Sonnenschein,et al.  Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Cordon-Cardo,et al.  Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. , 1999, Journal of the National Cancer Institute.

[18]  J. Massagué,et al.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. , 1995, Cancer research.

[19]  The fission yeast COP9/signalosome is involved in cullin modification by ubiquitin-related Ned8p , 2001, BMC Biochemistry.

[20]  Michele Pagano,et al.  Inverse relation between levels of p27Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas , 2001, Cancer.

[21]  M Chilosi,et al.  Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. , 2000, Blood.

[22]  D. Schiffer,et al.  Proteasome-dependent degradation of p27/kip1 in gliomas. , 1999, Journal of neuropathology and experimental neurology.

[23]  Y. Xiong,et al.  Human CUL-1, but not other cullin family members, selectively interacts with SKP1 to form a complex with SKP2 and cyclin A. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[24]  Andrea C. Carrano,et al.  Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. , 1999, Genes & development.

[25]  M. Gstaiger,et al.  Association of human CUL‐1 and ubiquitin‐conjugating enzyme CDC34 with the F‐box protein p45SKP2: evidence for evolutionary conservation in the subunit composition of the CDC34–SCF pathway , 1998, The EMBO journal.

[26]  Hong Sun,et al.  p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27 , 1999, Current Biology.

[27]  R. Weinberg,et al.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins , 1992, Cell.

[28]  James M. Roberts,et al.  Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle , 1996, Science.

[29]  A. Carr,et al.  Deletion mutants in COP9/signalosome subunits in fission yeast Schizosaccharomyces pombe display distinct phenotypes. , 2002, Molecular biology of the cell.

[30]  J. Swinnen,et al.  E2F activity is biphasically regulated by androgens in LNCaP cells. , 2001, Biochemical and biophysical research communications.

[31]  C. Sonnenschein,et al.  Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  J. Kato,et al.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 , 1999, Nature.

[33]  L. Klotz,et al.  Involvement of p27Kip1 in G1 arrest by high dose 5α-dihydrotestosterone in LNCaP human prostate cancer cells , 2000, Oncogene.

[34]  Brett Larsen,et al.  The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27 , 2001, Nature Cell Biology.

[35]  L. Klotz,et al.  Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.

[36]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[37]  J. Mestan,et al.  Skp2 is oncogenic and overexpressed in human cancers , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Robles,et al.  Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[39]  Y. Dong,et al.  Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Michele Pagano,et al.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.

[41]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[42]  R. Kraft,et al.  A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  D. Eick,et al.  Transcriptional down-regulation of c-myc in human prostate carcinoma cells by the synthetic androgen mibolerone. , 1992, British Journal of Cancer.

[44]  R. Kobayashi,et al.  pl9 skp1 and p45 skp2 are essential elements of the cyclin A-CDK2 S phase kinase , 1995, Cell.

[45]  C. Bartram,et al.  Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. , 1995, Cancer research.

[46]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[47]  N. Olea,et al.  Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response. , 1995, Oncology research.

[48]  Bruno Amati,et al.  Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 , 1997, The EMBO journal.

[49]  K. Nakayama,et al.  Degradation of p27 Kip1 at the G0-G1 Transition Mediated by a Skp2-independent Ubiquitination Pathway* , 2001, The Journal of Biological Chemistry.

[50]  W. Baumeister,et al.  A Subcomplex of the Proteasome Regulatory Particle Required for Ubiquitin-Conjugate Degradation and Related to the COP9-Signalosome and eIF3 , 1998, Cell.

[51]  Minoru Yoshida,et al.  The Cytoplasmic Shuttling and Subsequent Degradation of p27Kip1 Mediated by Jab1/CSN5 and the COP9 Signalosome Complex* , 2002, The Journal of Biological Chemistry.

[52]  N. Olea,et al.  Negative controls of cell proliferation: human prostate cancer cells and androgens. , 1989, Cancer research.

[53]  D. Wolf,et al.  Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP. , 1991, British Journal of Cancer.

[54]  Wilhelm Krek,et al.  p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells , 1999, Nature Cell Biology.

[55]  Michele Pagano,et al.  Role of the F-Box Protein Skp2 in Adhesion-Dependent Cell Cycle Progression , 2001, The Journal of cell biology.

[56]  H. Hermeking,et al.  A complex between E2F and the pRb-related protein p130 is specifically targeted by the simian virus 40 large T antigen during cell transformation. , 1995, Oncogene.

[57]  R. Deshaies,et al.  The fission yeast COP9/signalosome is involved in cullin modification by ubiquitin-related Ned8p , 2001, BMC Biochemistry.

[58]  S. Arya,et al.  The LNCaP cell line--a new model for studies on human prostatic carcinoma. , 1980, Progress in clinical and biological research.

[59]  S. Groshen,et al.  Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. , 1998, Journal of the National Cancer Institute.

[60]  Minami Matsui,et al.  The COP9 Complex, a Novel Multisubunit Nuclear Regulator Involved in Light Control of a Plant Developmental Switch , 1996, Cell.

[61]  J. Cheville,et al.  Expression of p27kip1 in prostatic adenocarcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[62]  S. Sato,et al.  High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. , 2001, Cancer research.

[63]  H Strohmaier,et al.  A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. , 2001, Molecular cell.

[64]  W. Krek,et al.  Induction of hepatocyte proliferation and liver hyperplasia by the targeted expression of cyclin E and skp2 , 2001, Oncogene.